Catalyst Event
Biogen Inc (BIIB) · Other
From KEDI Global Longevity Bio Index (KGLB)
5/24/2026, 12:00:00 AM
FDA PDUFA action date for the supplemental Biologics License Application (sBLA) for a subcutaneous formulation of LEQEMBI is May 24, 2026; Medium importance is estimated due to uncertain market reaction scheduled.
Korean Translation
2026년 5월 24일 레켐비(LEQEMBI) 피하주사 제형의 보충적 생물의약품 허가신청(sBLA)에 대한 FDA PDUFA 목표일이 예정됨. 시장 반응 불확실로 중요도는 추정치이며 예정됨.
Related Recent Events
Amgen Inc (AMGN) · Other
A quarterly dividend of $2.52 per share for Q2 2026 is scheduled, with an ex-dividend date of May 15, 2026; a price impact of ≥1% is estimated due to the routine nature of the distribution, scheduled.
5/15/2026, 12:00:00 AM
Pfizer Inc (PFE) · Earnings Release
First quarter 2026 earnings release and conference call scheduled.
5/5/2026, 12:00:00 AM
Merck and Co Inc (MRK) · Earnings Release
Merck is scheduled to release its Q1 2026 financial results before the market opens. Earnings releases typically cause significant price volatility, justifying a Medium importance, scheduled.
4/30/2026, 12:00:00 AM
Bristol-Myers Squibb Co (BMY) · Earnings Release
First quarter 2026 financial results and conference call scheduled for 2026-04-30. Routine earnings announcements typically result in minor price fluctuations (Low importance) scheduled.
4/30/2026, 12:00:00 AM
Medpace Holdings Inc (MEDP) · Earnings Release
First quarter 2026 financial results to be reported after market close on April 22, 2026. Importance is estimated as High as earnings releases typically cause significant price volatility, scheduled.
4/22/2026, 12:00:00 AM
Thermo Fisher Scientific Inc (TMO) · Earnings Release
Q1 2026 earnings release is scheduled.
4/22/2026, 12:00:00 AM